

FOLIC ACID-CONTAINING PHARMACEUTICAL COMPOSITIONS, AND
RELATED METHODS AND DELIVERY SYSTEMS

5

Throughout this application, various publications
are cited. The disclosure of these publications is
10 hereby incorporated by reference into this application to
describe more fully the state of the art to which this
invention pertains.

Field of the Invention

15

This invention relates to compositions and methods
for delivering folic acid to subjects afflicted with, or
at an increased risk of becoming afflicted with, a folic
acid-treatable disorder. The folic acid is incorporated
20 into a chronically administered pharmaceutical
composition intended for treating or preventing a
condition different than the folic acid-treatable
disorder.

25 Background of the Invention

Folic Acid Generally

Folic acid is a vitamin. It plays a crucial role in
30 DNA synthesis, and in hematopoiesis (although the details
of this role remain undefined). Folic acid is involved,
for example, in single carbon transfers (such as those
required for purine and pyrimidine metabolism), and in
the re-methylation of homocysteine to methionine.

35

Folic acid is available, primarily as the polyglutamate, from dietary sources such as whole grains, mushrooms, vegetables, red meat, fish and legumes. Supplementation, however, is provided in the form of the monoglutamate (pteroglutamic acid). Folic acid is absorbed primarily in the proximal small bowel, is highly protein-bound, and is stored in the liver. Almost no unchanged folic acid appears in the urine under normal circumstances, unless excess is provided.

Minimum requirements of folic acid are in the range of 50 µg/day, and increase 3 to 6 times during pregnancy and/or lactation. The U.S. recommended daily allowance for pregnant women is 400 µg/day, and the average pharmacological replacement dose is between 1 and 5 mg/day. Most prenatal vitamins contain 1 mg of folic acid.

The total body store of folic acid is about 5 mg. When a folic acid-deficient patient is treated, reversal of the deficiency begins rapidly (reticulocytosis within 4 days) and resolves within 2 months. If folic acid is administered at a rate of only 50 µg day, assuming no dietary or other intake, signs of folic acid deficiency are manifest after an approximately 3 month lag time. In cases of increased bodily folic acid requirements, such as pregnancy or lactation, this time frame is shortened to 2 to 4 weeks. Fortunately, folic acid supplementation in otherwise healthy young women who have such increased folic acid needs is an accepted practice.

Folic acid has not been reported to cause adverse effects when administered in reasonable, pharmacological doses. The only reported adverse reaction for folic acid

is a decreased level of plasma zinc in the case of prolonged high-dose administration.

5 Oral Contraceptives and Folic Acid

10 In pregnant women, correction of low folic acid levels takes at least two months, and reserves can last as little as a few weeks. According to a public health service recommendation, all women who can become pregnant should consume 400 µg/day of folic acid to reduce the risk of birth defects (MMWR Morb Mortal Wkly Rep 1992; 41(RR-14):1-7). Supplementation immediately before discontinuing oral contraceptive use or immediately after
15 positive pregnancy test results may be insufficient to optimally protect the developing fetus.

20 In addition, multiple studies of women taking oral contraceptives show decreased folic acid levels relative to negative controls. Postulated mechanisms reported for this phenomenon include decreased absorption of polyglutamates, increased excretion of folic acids, increased production of folic acid-binding proteins, and induction of folic acid-dependent hepatic microsomal
25 enzymes.

Decreases of folic acid levels among oral contraceptive users pose an additional risk for such users who become pregnant within three to six months
30 following discontinuation of use.

5

20

30

(1995) 237:381-388). A single study by Guttormsen
(Guttormsen, A.B., et al., J Clin Invest (1996) 98:2174-
2183) demonstrated that low-dose folic acid
supplementation (200 µg/day) reduces elevated plasma
5 homocysteine levels in patients with intermediate
hyperhomocysteinemia (> 40 µmol/L). This reduction is
influenced, in part, by the initial causes of
hyperhomocysteinemia, i.e., genetic mutation, dietary
deficiency and concurrent disease.

10

Summary of the Invention

This invention provides a pharmaceutical composition comprising (a) an oral contraceptive for preventing pregnancy in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the oral contraceptive is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.

This invention also provides a pharmaceutical composition comprising (a) a hormonal replacement composition for treating or preventing a menopausal condition in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the hormonal replacement composition is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.

This invention further provides a pharmaceutical composition comprising (a) a hormonal replacement composition for treating or preventing a hypogonadal condition in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the hormonal replacement composition is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.

This invention further provides a method of administering folic acid to a subject for whom an oral contraceptive is indicated for preventing pregnancy, which comprises administering to the subject the instant

Detailed Description of the Invention

Definitions


5 In this invention, certain terms are used which shall have the meanings set forth as follows.

 "Androgen-related compound" ("ARC") shall mean a compound which displays an end organ androgen effect. ARC's are
10 exemplified in the Examples below.

 "Chronic administration" shall mean administration which occurs either at regular intervals (e.g., daily oral dosage) or continuously (e.g. transdermal delivery for
15 several days) over at least a single time period (e.g., three weeks). The chronic administration can optionally occur over a plurality of time periods.

 "Estrogen-related compound" ("ERC") shall mean a compound
20 which displays an end organ estrogen effect. ERC's are exemplified in the Examples below.

 "Folic acid" shall mean the compound having the following structure, where R and R' are both H, as well as
25 pharmaceutically acceptable salts and derivatives thereof:



30 Pharmaceutically acceptable salts are well known in the art and include, without limitation, Na⁺, K⁺, Mg⁺⁺ and

various amines (Int'l. J. Pharm. (1986) 33:201-217).
Pharmaceutically acceptable derivatives are also well
known in the art and include, without limitation, esters.
Such derivatives are exemplified below.

5

"Menopausal condition" shall mean a condition that is
either a peri-menopausal condition or a post-menopausal
condition.

10 "Menopausal woman" shall mean a woman having an age at
which menopause or its onset normally occurs.

15 "Peri-menopausal condition" shall mean a condition which
(i) occurs either during menopausal onset, or prior
thereto at a time when menopausal onset normally occurs,
and (ii) either is caused by menopausal onset or has a
greater than random coincidence therewith. Peri-
menopausal conditions include, for example, hot flashes
and reduction of bone mass.

20

"Post-menopausal condition" shall mean a condition which
(i) occurs after menopausal onset, and (ii) either is
caused by menopause or has a greater than random
coincidence therewith. Post-menopausal conditions
25 include, for example, vasomotor symptoms, osteopenia,
osteoporosis, cardiovascular disease and cognitive
dysfunction.

30 "Progestin-related compound" ("PRC") shall mean a
compound which displays an end organ progestin effect.
PRC's are exemplified in the Examples below.

"Subject" shall any animal, such as a primate, mouse, rat, guinea pig or rabbit. In the preferred embodiment, the subject is a human.

5

Embodiments of the Invention

10 This invention provides a pharmaceutical composition comprising (a) an oral contraceptive for preventing pregnancy in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the oral contraceptive is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.

15

20 This invention also provides a method of administering folic acid to a subject for whom an oral contraceptive is indicated for preventing pregnancy, which comprises administering to the subject the instant pharmaceutical composition, wherein the subject is from a population whose members are afflicted with, or predisposed to become afflicted with, a disorder at a higher-than-normal incidence, the disorder being treatable or preventable by folic acid administration.

25

30 Oral contraceptives are widely available commercially, and classifications thereof include, without limitation, progestin only, fixed dose, and phasics. Oral contraceptives routinely contain one or more estrogen-related compounds and progestin-related compounds. Such contraceptives are preferred in this invention and are listed extensively, along with their respective hormone ingredients, in the IPPF Directory of Hormonal Contraceptives. For the purpose of

illustration, selected oral contraceptives and their respective hormone ingredients are listed in the Examples below.

5 In this embodiment, the disorder can be any folic acid-treatable condition with which pregnant women are afflicted, or to which they are predisposed to become afflicted, at a higher-than-normal incidence. In the preferred embodiment, the disorder is selected from the
10 group consisting of a teratogenic disorder, cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder.

 This invention also provides a pharmaceutical
15 composition comprising (a) a hormonal replacement composition for treating or preventing a menopausal condition in a subject, and (b) folic acid in an amount sufficient to treat or prevent a disorder which (i) afflicts subjects for whom the hormonal replacement
20 composition is indicated at a higher-than-normal incidence, and (ii) is treatable or preventable by folic acid administration.

 This invention further provides a method of
25 administering folic acid to a subject for whom a hormonal replacement composition is indicated for treating or preventing a menopausal condition, which comprises administering to the subject the instant pharmaceutical composition, wherein the subject is from a population
30 whose members are afflicted with, or predisposed to become afflicted with, a disorder at a higher-than-normal incidence, the disorder being treatable or preventable by folic acid administration.

5 The menopausal condition can be a peri-menopausal
condition or, alternatively, a post-menopausal condition.
Hormonal replacement compositions are widely available
commercially, and routinely contain estrogen-related
compounds, progestin-related compounds, androgen-related
compounds, and others. Such compositions are preferred
in this invention and are listed extensively, along with
their respective hormone ingredients, in Sturdee, D.W.,
et al. (Br J Obstet Gynecol (1997) 104:109-115). By way
10 of example, selected hormone replacement compositions and
their respective hormone ingredients are listed in the
Examples below.

15 In this embodiment, the disorder can be any folic
acid-treatable condition with which menopausal women are
afflicted, or to which they are predisposed to become
afflicted, at a higher-than-normal incidence. In the
preferred embodiment, the disorder is selected from the
group consisting of cervical dysplasia, cervical
20 carcinoma and a cardiovascular disorder.

25 This invention also provides a pharmaceutical
composition comprising (a) a hormonal replacement
composition for treating or preventing a hypogonadal
condition in a subject, and (b) folic acid in an amount
sufficient to treat or prevent a disorder which (i)
afflicts subjects for whom the hormonal replacement
composition is indicated at a higher-than-normal
incidence, and (ii) is treatable or preventable by folic
30 acid administration.

This invention further provides a method of
administering folic acid to a subject for whom a hormonal
replacement composition is indicated for treating or

preventing a hypogonadal condition, which comprises administering to the subject the instant pharmaceutical composition, wherein the subject is from a population whose members are afflicted with, or predisposed to
5 become afflicted with, a disorder at a higher-than-normal incidence, the disorder being treatable or preventable by folic acid administration.


10 Hormone replacement compositions for hypogonadal conditions routinely contain androgen-related compounds (for male subjects) and estrogen- and progestin-related compounds (for female subjects). Hypogonadal conditions include, by way of example, menopause (with or without reduced libido), Klinefelter's syndrome, and post-
15 orchectomy status. When the subject is female, the disorder can be selected, for example, from the group consisting of a teratogenic disorder, cervical dysplasia, a cervical carcinoma, and a cardiovascular disorder. When the subject is male, the disorder can be, for
20 example, a cardiovascular disorder.

In this invention, administering the instant pharmaceutical compositions can be effected or performed using any of the various methods and delivery systems
25 known to those skilled in the art. The administering can be performed, for example, intravenously, orally, via implant, transmucosally, transdermally, intramuscularly, and subcutaneously. In addition, the instant pharmaceutical compositions ideally contain one or more
30 routinely used pharmaceutically acceptable carriers. Such carriers are well known to those skilled in the art. The following delivery systems, which employ a number of routinely used carriers, are only representative of the

many embodiments envisioned for administering the instant composition.


Transdermal delivery systems include patches, gels, tapes and creams, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), hydrophilic polymers (e.g., polycarbophil and polyvinylpyrrolidone), and adhesives and tackifiers (e.g., polyisobutylenes, silicone-based adhesives, acrylates and polybutene).

The transdermal administration of folic acid can be facilitated by using the following ester form, which is hydrolyzed in vivo:



This ester can be a mono-ester (where either R or R' = H) or a di-ester (where neither R or R' is H). By way of example, R and R' can be independently selected from the following groups: lower alkyl from 1-8 carbons (e.g., methyl, ethyl, propyl and butyl); branched lower alkyl from 1-8 carbons (e.g., isopropyl, isobutyl and sec-butyl); cycloalkyl having 3-7 carbons (e.g., cyclopentyl and cyclohexyl); aryl (e.g., phenyl and substituted phenyl having 1-2 substituents selected from lower alkyl and halo alkoxyl); and arylalkyl, where the alkyl is a straight or branched chain of 1-8 carbons, and aryl is a phenyl or substituted phenyl.

Glycolamide esters (both mono- and di-) can also be used for transdermal folic acid administration. Esters of this type are known to be useful as pro-drugs, and are cleaved rapidly in-vivo (J. Med. Chem. (1989) 32(3):727-34). In glycolamide esters, at least one of R or R' has the structure:



where (i) each R'' is independently a lower alkyl (from 1-5 carbons) or, alternatively, (ii) both R'' groups form an N-containing, 5-7-membered ring having 4-6 carbons.

Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid).

Injectable drug delivery systems include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol and sucrose) and polymers (e.g., polycaprylactones and PLGA's). Implantable systems include rods and discs, and can contain excipients such as PLGA and polycaprylactone.

Oral delivery systems include tablets and capsules. These can contain excipients such as binders (e.g., hydroxypropylmethylcellulose, polyvinyl pyrrolidone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents (e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc).

Solutions, suspensions and powders for reconstitutable delivery systems include vehicles such as suspending agents (e.g., gums, xanthans, cellulose and sugars), humectants (e.g., sorbitol), solubilizers (e.g., ethanol, water, PEG and propylene glycol), surfactants (e.g., sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine), preservatives and antioxidants (e.g., parabens, vitamins E and C, and ascorbic acid), anti-caking agents, coating agents, and chelating agents (e.g., EDTA).

Methods of determining therapeutically effective doses for administering the instant pharmaceutical composition in humans are known in the art. For example, these effective doses can readily be determined mathematically from the results of animal studies.

In one embodiment of the instant invention, the daily dose of folic acid administered to a subject according to the instant invention is from about 25 μg to about 1 g. Current recommendations in the art for daily folic acid dosages, upon which indication-specific dosages can readily be determined, include, for example: 50 $\mu\text{g}/\text{day}$ (minimum effective dose, general population); 200 $\mu\text{g}/\text{day}$ (recommended daily allowance, general

population); 400 µg/day (women of reproductive age); 800 µg/day (pregnant women); 500 µg/day (lactating women); 4 mg/day (women who have previously delivered a fetus having NTD); 1-5 mg/day (reduction of elevated
5 homocysteine levels); and 200 µg/day (reduction of elevated plasma homocysteine levels in intermediate hyperhomocysteinemia patients).

10 The instant pharmaceutical compositions can be packaged in the form of pharmaceutical kits or packages in which the daily (or other periodic) dosages are arranged for proper sequential administration. Accordingly, this invention further provides a drug delivery system comprising a pharmaceutical package
15 containing a plurality of dosage units, adapted for successive daily administration, each dosage unit comprising at least one of the instant pharmaceutical compositions.

20 This drug delivery system can be used to facilitate administering any of the various embodiments of the instant pharmaceutical compositions. In one embodiment, the system contains a plurality of dosages to be taken daily via oral administration (as commonly practiced in
25 the oral contraceptive art). In another embodiment, the system contains a plurality of dosages to be administered weekly via transdermal administration (as commonly practiced in the hormone replacement art), thus providing continuous folic acid delivery.

30 For added convenience, the instant system can further comprise additional dosage units that contain folic acid, but no other active ingredient. Such delivery system could provide a total of 28 oral dosage

units, consistent with normal practice in the art of oral
contraception. More specifically, an oral contraceptive
delivery system could provide 21 daily dosage units, each
comprising folic acid and oral contraceptive, and 7

5 additional dosage units comprising only folic acid and a
suitable carrier. This type of system is consistent with
the beneficial practice of daily, uninterrupted
administration widely used with oral contraceptives.

10 This invention will be better understood by
reference to the Examples which follow, but those skilled
in the art will readily appreciate that the information
detailed is only illustrative of the invention as
described more fully in the claims which follow
15 thereafter.

Example 1

Estrogen-Related Compounds

17- β -estradiol

- 5 Conjugated estrogens (including estrone sulfate, equilin,
and 17- α -dihydroequilin)

Esterified estrogens

Estradiol

Estradiol valerate

- 10 Estriol

Estrone

Estrone sulfate

Estropipate

Ethinyl estradiol

- 15 Mestranol

Example 2

Selective Estrogen
Receptor Modulators (SERMS)

- 20

Droloxifene

Idoxifene

Levormeloxifene

Raloxifene

- 25

Example 3

Progestin-Related Compounds

Available World-Wide

- 30 17-deacetyl norgestimate

Desogestrel

Ethinodiol diacetate

Levonorgestrel

Medroxyprogesterone acetate

Norethindrone
Norethindrone acetate
Norgestimate
Norgestrel
5 Progesterone

Available Outside the U.S.

3-keto desogestrel
Chlormadinone acetate
10 Cyproterone acetate
Dienogest
Dydrogesterone
Gestodene
Lynestrenol
15 Megestrol
Norethisterone
Norethisterone acetate
Norgestrienone
Quingestanol acetate
20

Example 4

Androgen-Related Compounds

Fluoxymesterone
25 Methyltestosterone
Testosterone
Testosterone enanthate

Example 5
Oral Contraceptives

Brand Name	Manufacturer**	ERC	PRC
DESOGEN	Organon	Ethinyl estradiol	Desogestrel
ORTHO CEPT	Ortho McNeil	Ethinyl estradiol	Desogestrel
DEMULEN 1/50	Searle	Ethinyl estradiol	Ethynodiol diacetate
ZOVIA 1/35	Watson	Ethinyl estradiol	Ethynodiol diacetate
DEMULEN 1/35	Searle	Ethinyl estradiol	Ethynodoil diacetate
ZOVIA 1/50	Watson	Ethinyl estradiol	Ethynodoil diacetate
LEVLEN	Berlex	Ethinyl estradiol	Levonorgestrel
TRI-LEVLEN	Berlex	Ethinyl estradiol	Levonorgestrel
LEVORA	Watson	Ethinyl estradiol	Levonorgestrel
ALESSE	Wyeth Ayerst	Ethinyl estradiol	Levonorgestrel
NORDETTE	Wyeth Ayerst	Ethinyl estradiol	Levonorgestrel
TRIPHASIL	Wyeth Ayerst	Ethinyl estradiol	Levonorgestrel
OVCON 35	Apothecon	Ethinyl estradiol	Norethindrone
OVCON 50	Apothecon	Ethinyl estradiol	Norethindrone
JENEST	Organon	Ethinyl estradiol	Norethindrone
ORTHO NOVUM 7/7/7	Ortho McNeil	Ethinyl estradiol	Norethindrone
ORTHO NOVUM 1/35	Ortho McNeil	Ethinyl estradiol	Norethindrone

Brand Name	Manufacturer	ERC	PRC
ORTHO NOVUM 1/50	Ortho McNeil	Mestranol	Norethindrone
ORTHO NOVUM 10-11	Ortho McNeil	Ethinyl estradiol	Norethindrone
NORETHIN 1/35E	Roberts	Ethinyl estradiol	Norethindrone
NORETHIN 1/50M	Roberts	Mestranol	Norethindrone
NORETHIN 1/35	Searle	Ethinyl estradiol	Norethindrone
NORETHIN 1/50	Searle	Mestranol	Norethindrone
BREVICON	Searle	Ethinyl estradiol	Norethindrone
NORINYL 1+35	Searle	Ethinyl estradiol	Norethindrone
NORINYL 1+50	Searle	Mestranol	Norethindrone
NOR-QD	Searle		Norethindrone
TRI-NORINYL	Searle	Ethinyl estradiol	Norethindrone
NELOVA 0.5/35	Warner Chilcott	Ethinyl estradiol	Norethindrone
NELOVA 1/35	Warner Chilcott	Ethinyl estradiol	Norethindrone
NELOVA 1/50	Warner Chilcott	Mestranol	Norethindrone
NELOVA 10/11	Warner Chilcott	Ethinyl estradiol	Norethindrone
NECON 0.5/35	Watson	Ethinyl estradiol	Norethindrone
NECON 1/35	Watson	Ethinyl estradiol	Norethindrone
NECON 1/50	Watson	Mestranol	Norethindrone
NECON 10/11	Watson	Ethinyl estradiol	Norethindrone
ESTROSTEP 21	Parke Davis	Ethinyl estradiol	Norethindrone acetate
ESTROSTEP Fe	Parke Davis	Ethinyl estradiol	Norethindrone acetate
LOESTRIN Fe 1.5/30	Parke Davis	Ethinyl estradiol	Norethindrone acetate

Brand Name	Manufacturer	ERC	PRC
LOESTRIN Fe 1/20	Parke Davis	Ethinyl estradiol	Norethindrone acetate
NORLESTRIN 1/50	Parke Davis	Ethinyl estradiol	Norethindrone acetate
NORLESTRIN 2.5/50	Parke Davis	Ethinyl estradiol	Norethindrone acetate
GENORA 1/35	Watson	Ethinyl estradiol	Norethisterone
GENORA 1/50	Watson	Mestranol	Norethisterone
GENORA 0.5/35	Watson	Ethinyl estradiol	Norethisterone
MICRONOR	Ortho McNeil		Norgestimate
ORTHO CYCLEN	Ortho McNeil	Ethinyl estradiol	Norgestimate
ORTHO TRI-CYCLEN	Ortho McNeil	Ethinyl estradiol	Norgestimate
LO/OVRAL	Wyeth Ayerst	Ethinyl estradiol	Norgestrel
OVRAL	Wyeth Ayerst	Ethinyl estradiol	Norgestrel
OVRETTE	Wyeth Ayerst		Norgestrel

** The manufacturers listed in this and other Examples are fully identified, by address, in Physicians' Desk Reference, 51st Ed. (1997) Medical Economics.

Example 6

Hormone Replacement Therapy Vaginal Estrogen Preparations

Brand	ERC	Formulation
PREMARIN	Conj. Estrogens	Cream
ORTHO DIENOESTROL	Dienoestrol	Cream
OVESTIN	Estriol	Cream
ORTHO-GYNEST	Estriol	Pessary
TAMPOVAGAN	Stilbestrol	Pessary
ESTRING	Estradiol	Vaginal ring
VAGIFEM	Estradiol	Vaginal tablet

Example 7

Hormone Replacement Therapy
Transdermal Estrogen Preparations

Brand	ERC
ALORA	Estradiol
CLIMARA	Estradiol
DERMESTRIL	Estradiol
ESTRADERM	Estradiol
ESTRADERM TTS or MX	Estradiol
EVOREL	Estradiol
FEMATRIX	Estradiol
FEMPATCH	Estradiol
FEMSEVEN	Estradiol
MENOREST	Estradiol
PROGYNOVA TS	Estradiol
VIVELLE	Estradiol

Example 8

Hormone Replacement Therapy
Period-Free Therapy

Type	Brand	ERC	PRC
Continuous	CLIMESSE	Estradiol	Norethisterone
Combined therapy	EVORELCONTI	Estradiol	Norethisterone
	KLIOFEM	Estradiol	Norethisterone
	PREMIQUE	Conj. Estrogens	Medroxyprogesterone
	PREMPRO	Conj. Estrogens	Medroxyprogesterone acetate
Gonadomimetic	LIVIAL		

Example 9

Hormone Replacement Therapy
Estrogen Preparations

Brand	ERC	Formulation
ESTROGEL	Estradiol	Gel
SANDRENA	Estradiol	Gel
ESTRADIOL IMPLANT	Estradiol	Pellet implant
PREMARIN	Conjugated estrogens	Tablet
ESTRATAB	Esterified estrogens	Tablet
ESTRATEST	Esterified estrogens	Tablet
ESTRATEST HS	Methyltestosterone	
MENEST	Esterified estrogens	Tablet
CLIMAGEST	Estradiol	Tablet
CLIMAVAL	Estradiol	Tablet
ELLESTE SOLO	Estradiol	Tablet
ESTRACE	Estradiol	Tablet
PROGYNOVA	Estradiol	Tablet
ZUMENON	Estradiol	Tablet
HORMONIN	Estradiol, estrone, estriol	Tablet
HARMOEN	Estrone	Tablet
OGEN	Estropipate	Tablet
ORTHO-EST	Estropipate	Tablet

Example 10

Combined Sequential Hormone Replacement Therapy

Type	Brand	ERC	PRC	Formul.
1/month	PREMIQUE CYCLE	Conj. Estrogens	Medroxy- progesterone	Tablet
	PREMPHASE	Conj. Estrogens	Medroxyproges- terone acetate	Tablet
	PREMPAK-C	Conj. Estrogens	Norgestrel	Tablet
	FEMPAK	Estradiol	Dydrogesterone	Tablet Patch
	FEMOSTON	Estradiol	Dydrogesterone	Tablet
	CYCLO- PROGYNOVA	Estradiol	Levonorgestrel	Tablet
	NUVELLE	Estradiol	Levonorgestrel	Tablet
	NUVELLE TS	Estradiol	Levonorgestrel	Patch
	CLIMAGEST	Estradiol	Norethisterone	Tablet
	ELLESTE DUET	Estradiol	Norethisterone	Tablet
	ESTRACOMBI	Estradiol	Norethisterone	Tablet Patches
	ESTRAPAK	Estradiol	Norethisterone	Tablet Patches
	EVOREL-PAK	Estradiol	Norethisterone	Tablet Patches
	EVORELSEQUI	Estradiol	Norethisterone	Tablet Patches
	TRISEQUENS	Estradiol, estriol	Norethisterone	Tablet
	IMPROVERA	Estrone	Medroxy- progesterone	Tablet
	MENOPHASE	Mestranol	Norethisterone	Tablet
1/qtr.	TRIDESTRA	Estradiol	Medroxy- progesterone	Tablet

Example 11

Hormone Replacement Therapy
Progestin-Only Formulations

Brand	PRC	Formulation
AMEN	Medroxyprogesterone acetate	Tablet
CYCRIN	Medroxyprogesterone acetate	Tablet
PROVERA	Medroxyprogesterone acetate	Tablet
AYGESTIN	Norethindrone acetate	Tablet

5

Example 12

Hormone Replacement Therapy
Androgenic Formulations

Brand Name	Manufacturer	Hormone Content
HALOTESTIN	Upjohn	Fluoxymesterone Oral
ANDROID	ICN	Methyltestosterone Oral
ORETON	ICN	Methyltestosterone Oral
TESTRED	ICN	Methyltestosterone Oral
DEPO-TESTOSTERONE	Upjohn	Testosterone cypionate Injectable
DELATESTRYL	BTG Pharmaceuticals	Testosterone enanthate Injectable
TESTODERM	Alza	Testosterone, USP Transdermal

10

Formulation For Folic
Acid-Containing Oral Contraceptive

-